Oncology · 3 h ago
Norwegian registry study finds improved survival after immunotherapy uptake in advanced NSCLC
A nationwide Norwegian registry study included 9,178 patients with advanced non-small-cell lung cancer diagnosed from 2012 to 2021. Treatment use and survival increased after immunotherapy became standard, including among patients with COPD, cardiovascular disease, type 2 diabetes or rheumatic disease.
- Registry study included 9,178 patients with advanced NSCLC.
- Comorbidities were common among patients in the cohort.
- Treatment use and survival rose after immunotherapy became standard.
- Outcomes varied by comorbidity and treatment regimen.
Researchers linked data from Norwegian health registries to examine treatment and outcomes among 9,178 people diagnosed with advanced non-small-cell lung cancer (NSCLC) between 2012 and 2021. The observational study compared the period before and after immunotherapy became standard treatment in Norway. Nearly half of patients had at least one of the comorbidities studied: COPD (22%), cardiovascular disease (21%), type 2 diabetes (10%) or rheumatic disease (6%).
After immunotherapy was introduced, systemic cancer treatment use increased among patients with comorbidities, and survival improved across the comorbidity groups. Two-year survival in some groups was up to three times higher than before immunotherapy. Among patients with cardiovascular disease, two-year survival was 38% with immunotherapy alone and 22% with immunotherapy plus chemotherapy; among those with rheumatic disease, the corresponding figures were 23% and 20%.
The findings add real-world evidence for patient groups often underrepresented in clinical trials. However, the before-and-after registry design cannot establish that immunotherapy alone caused the survival gains, and outcomes varied by comorbidity and treatment regimen. The results do not establish which regimen is best for an individual patient; the authors say further work is needed to support more tailored treatment.
In practice
For patients with advanced NSCLC and COPD, cardiovascular disease, type 2 diabetes or rheumatic disease, this Norwegian registry analysis suggests that treatment use and survival improved after immunotherapy became standard, so these comorbidities should not be assumed to preclude benefit. The study also found outcome differences by comorbidity and regimen, but it was observational and compared treatment eras; it cannot establish that immunotherapy caused the gains or determine the best regimen for an individual. It does not justify a treatment change on its own.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Folkehelseinstituttet: Immunterapi gir håp også for lungekreftpasienter med underliggende sykdommer ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.